BRISTOL-MYERS SQUIBB COMPANY Marketing and Advertising Expense
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Marketing and Advertising Expense of $1.30 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:MarketingAndAdvertisingExpense · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY marketing and advertising expense for the quarter ending 2015-12-31 was $330.00M, a 54.93% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY marketing and advertising expense for the quarter ending 2015-09-30 was $193.00M, a 12.87% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY marketing and advertising expense for the quarter ending 2015-06-30 was $167.00M, a 10.70% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY marketing and advertising expense for the quarter ending 2015-03-31 was $135.00M, a 17.18% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY marketing and advertising expense for fiscal 2025 was $1.30B, a 13.33% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY marketing and advertising expense for fiscal 2024 was $1.50B, a 7.14% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY marketing and advertising expense for fiscal 2023 was $1.40B, a 7.69% increase from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY marketing and advertising expense for fiscal 2022 was $1.30B, a 0.00% change from fiscal 2021.
| Period end | Marketing and Advertising Expense 3 month | Marketing and Advertising Expense 3 month as first filed | Marketing and Advertising Expense 6 month | Marketing and Advertising Expense 6 month as first filed | Marketing and Advertising Expense 9 month | Marketing and Advertising Expense 9 month as first filed | Marketing and Advertising Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $1.30B 10-K · filed 2026-02-11 | ||||||
| 2024-12-31 | $1.50B 10-K · filed 2026-02-11 | ||||||
| 2023-12-31 | $1.40B 10-K · filed 2026-02-11 | ||||||
| 2022-12-31 | $1.30B 10-K · filed 2025-02-12 | ||||||
| 2021-12-31 | $1.30B 10-K · filed 2024-02-13 | ||||||
| 2020-12-31 | $990.00M 10-K · filed 2023-02-14 | ||||||
| 2019-12-31 | $633.00M 10-K · filed 2022-02-09 | ||||||
| 2018-12-31 | $672.00M 10-K · filed 2021-02-10 | ||||||
| 2017-12-31 | $740.00M 10-K · filed 2020-02-24 | ||||||
| 2016-12-31 | $789.00M 10-K · filed 2019-02-25 | ||||||
| 2015-12-31 | $330.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $523.00M derived: sum of 2 quarters · filed 2018-02-13 | $690.00M derived: sum of 3 quarters · filed 2018-02-13 | $825.00M 10-K · filed 2018-02-13 | |||
| 2015-09-30 | $193.00M 10-Q · filed 2015-10-27 | $360.00M derived: sum of 2 quarters · filed 2015-10-27 | $495.00M 10-Q · filed 2015-10-27 | $708.00M derived: sum of 4 quarters · filed 2017-02-21 | |||
| 2015-06-30 | $167.00M 10-Q · filed 2015-07-23 | $302.00M 10-Q · filed 2015-07-23 | $515.00M derived: sum of 3 quarters · filed 2017-02-21 | $686.00M derived: sum of 4 quarters · filed 2017-02-21 | |||
| 2015-03-31 | $135.00M 10-Q · filed 2015-04-28 | $348.00M derived: sum of 2 quarters · filed 2017-02-21 | $519.00M derived: sum of 3 quarters · filed 2017-02-21 | $706.00M derived: sum of 4 quarters · filed 2017-02-21 | |||
| 2014-12-31 | $213.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $384.00M derived: sum of 2 quarters · filed 2017-02-21 | $571.00M derived: sum of 3 quarters · filed 2017-02-21 | $734.00M 10-K · filed 2017-02-21 | |||
| 2014-09-30 | $171.00M 10-Q · filed 2015-10-27 | $358.00M derived: sum of 2 quarters · filed 2015-10-27 | $521.00M 10-Q · filed 2015-10-27 | $775.00M derived: sum of 4 quarters · filed 2016-02-12 | |||
| 2014-06-30 | $187.00M 10-Q · filed 2015-07-23 | $350.00M 10-Q · filed 2015-07-23 | $604.00M derived: sum of 3 quarters · filed 2016-02-12 | $798.00M derived: sum of 4 quarters · filed 2016-02-12 | |||
| 2014-03-31 | $163.00M 10-Q · filed 2015-04-28 | $417.00M derived: sum of 2 quarters · filed 2016-02-12 | $611.00M derived: sum of 3 quarters · filed 2016-02-12 | $829.00M derived: sum of 4 quarters · filed 2016-02-12 | |||
| 2013-12-31 | $254.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $448.00M derived: sum of 2 quarters · filed 2016-02-12 | $666.00M derived: sum of 3 quarters · filed 2016-02-12 | $855.00M 10-K · filed 2016-02-12 | |||
| 2013-09-30 | $194.00M 10-Q · filed 2014-10-24 | $412.00M derived: sum of 2 quarters · filed 2014-10-24 | $601.00M 10-Q · filed 2014-10-24 | $813.00M derived: sum of 4 quarters · filed 2015-02-13 | |||
| 2013-06-30 | $218.00M 10-Q · filed 2014-07-24 | $407.00M 10-Q · filed 2014-07-24 | $619.00M derived: sum of 3 quarters · filed 2015-02-13 | $786.00M derived: sum of 4 quarters · filed 2015-02-13 | |||
| 2013-03-31 | $189.00M 10-Q · filed 2014-04-29 | $401.00M derived: sum of 2 quarters · filed 2015-02-13 | $568.00M derived: sum of 3 quarters · filed 2015-02-13 | $792.00M derived: sum of 4 quarters · filed 2015-02-13 | |||
| 2012-12-31 | $212.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $379.00M derived: sum of 2 quarters · filed 2015-02-13 | $603.00M derived: sum of 3 quarters · filed 2015-02-13 | $797.00M 10-K · filed 2015-02-13 | |||
| 2012-09-30 | $167.00M 10-Q · filed 2013-10-23 | $391.00M derived: sum of 2 quarters · filed 2013-10-23 | $585.00M 10-Q · filed 2013-10-23 | $870.00M derived: sum of 4 quarters · filed 2014-02-14 | |||
| 2012-06-30 | $224.00M 10-Q · filed 2013-07-25 | $418.00M 10-Q · filed 2013-07-25 | $703.00M derived: sum of 3 quarters · filed 2014-02-14 | $908.00M derived: sum of 4 quarters · filed 2014-02-14 | |||
| 2012-03-31 | $194.00M 10-Q · filed 2013-04-25 | $479.00M derived: sum of 2 quarters · filed 2014-02-14 | $684.00M derived: sum of 3 quarters · filed 2014-02-14 | $937.00M derived: sum of 4 quarters · filed 2014-02-14 | |||
| 2011-12-31 | $285.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-14 | $490.00M derived: sum of 2 quarters · filed 2014-02-14 | $743.00M derived: sum of 3 quarters · filed 2014-02-14 | $957.00M 10-K · filed 2014-02-14 | |||
| 2011-09-30 | $205.00M 10-Q · filed 2012-10-24 | $458.00M derived: sum of 2 quarters · filed 2012-10-24 | $672.00M 10-Q · filed 2012-10-24 | $943.00M derived: sum of 4 quarters · filed 2013-02-15 | |||
| 2011-06-30 | $253.00M 10-Q · filed 2012-07-25 | $467.00M 10-Q · filed 2012-07-25 | $738.00M derived: sum of 3 quarters · filed 2013-02-15 | $969.00M derived: sum of 4 quarters · filed 2013-02-15 | |||
| 2011-03-31 | $214.00M 10-Q · filed 2012-04-26 | $485.00M derived: sum of 2 quarters · filed 2013-02-15 | $716.00M derived: sum of 3 quarters · filed 2013-02-15 | $979.00M derived: sum of 4 quarters · filed 2013-02-15 | |||
| 2010-12-31 | $271.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $502.00M derived: sum of 2 quarters · filed 2013-02-15 | $765.00M derived: sum of 3 quarters · filed 2013-02-15 | $977.00M 10-K · filed 2013-02-15 | |||
| 2010-09-30 | $231.00M 10-Q · filed 2011-10-27 | $494.00M derived: sum of 2 quarters · filed 2011-10-27 | $706.00M 10-Q · filed 2011-10-27 | $1.04B derived: sum of 4 quarters · filed 2012-02-17 | |||
| 2010-06-30 | $263.00M 10-Q · filed 2011-07-28 | $475.00M 10-Q · filed 2011-07-28 | $809.00M derived: sum of 3 quarters · filed 2012-02-17 | $1.06B derived: sum of 4 quarters · filed 2012-02-17 | |||
| 2010-03-31 | $212.00M 10-Q · filed 2011-04-28 | $546.00M derived: sum of 2 quarters · filed 2012-02-17 | $802.00M derived: sum of 3 quarters · filed 2012-02-17 | $1.10B derived: sum of 4 quarters · filed 2012-02-17 | |||
| 2009-12-31 | $334.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $590.00M derived: sum of 2 quarters · filed 2012-02-17 | $888.00M derived: sum of 3 quarters · filed 2012-02-17 | $1.14B 10-K · filed 2012-02-17 | |||
| 2009-09-30 | $256.00M 10-Q · filed 2010-10-26 | $361.00M 10-Q · filed 2009-10-22 | $554.00M derived: sum of 2 quarters · filed 2010-10-26 | $802.00M 10-Q · filed 2010-10-26 | $1.08B 10-Q · filed 2009-10-22 | $882.00M derived: sum of 4 quarters · filed 2011-02-18 | |
| 2009-06-30 | $298.00M 10-Q · filed 2010-07-22 | $400.00M 10-Q · filed 2009-07-23 | $546.00M 10-Q · filed 2010-07-22 | $724.00M 10-Q · filed 2009-07-23 | $626.00M derived: sum of 3 quarters · filed 2011-02-18 | $988.00M derived: sum of 4 quarters · filed 2011-02-18 | |
| 2009-03-31 | $248.00M 10-Q · filed 2010-04-29 | $328.00M derived: sum of 2 quarters · filed 2011-02-18 | $690.00M derived: sum of 3 quarters · filed 2011-02-18 | $1.11B derived: sum of 4 quarters · filed 2011-02-18 | |||
| 2008-12-31 | $80.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $442.00M derived: sum of 2 quarters · filed 2011-02-18 | $862.00M derived: sum of 3 quarters · filed 2011-02-18 | $1.18B 10-K · filed 2011-02-18 | |||
| 2008-09-30 | $362.00M 10-Q · filed 2009-10-22 | $782.00M derived: sum of 2 quarters · filed 2009-10-22 | $1.10B 10-Q · filed 2009-10-22 | ||||
| 2008-06-30 | $420.00M 10-Q · filed 2009-07-23 | $739.00M 10-Q · filed 2009-07-23 | |||||
| 2007-12-31 | $1.10B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |